On July 15, Sino Biopharmaceutical rose 3.72% in regular trading, trading at HKD 5.32/share, with turnover of HKD 108 million.

On the news front, the company announced on July 14 that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has completed a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP) and was granted Breakthrough Therapy Designation by the CDE based on positive data. The drug acts only on the peripheral nervous system, potentially avoiding common adverse effects of CNS-targeting agents, and there is currently no approved therapy specifically for CPSNP.

Separately, Morgan Stanley on July 14 raised its basic EPS estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for 2026-2028 respectively after factoring in licensing income from Sanofi and GSK upfront payments, while reiterating an Overweight rating with a target price of HKD 7.8.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)